V

Vuno Inc
KOSDAQ:338220

Watchlist Manager
Vuno Inc
KOSDAQ:338220
Watchlist
Price: 24 600 KRW 1.65% Market Closed
Market Cap: 341.6B KRW
Have any thoughts about
Vuno Inc?
Write Note

Vuno Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vuno Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
V
Vuno Inc
KOSDAQ:338220
Total Liabilities
â‚©16.7B
CAGR 3-Years
8%
CAGR 5-Years
62%
CAGR 10-Years
N/A
B
Biodyne Co Ltd
KOSDAQ:314930
Total Liabilities
â‚©603.9m
CAGR 3-Years
-68%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
I
I Sens Inc
KOSDAQ:099190
Total Liabilities
â‚©214.5B
CAGR 3-Years
33%
CAGR 5-Years
25%
CAGR 10-Years
20%
J
Jeisys Medical Inc
KOSDAQ:287410
Total Liabilities
â‚©93.4B
CAGR 3-Years
58%
CAGR 5-Years
175%
CAGR 10-Years
N/A
C
Classys Inc
KOSDAQ:214150
Total Liabilities
â‚©93.6B
CAGR 3-Years
75%
CAGR 5-Years
32%
CAGR 10-Years
N/A
L
Lutronic Corp
KOSDAQ:085370
Total Liabilities
â‚©67.5B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
7%
No Stocks Found

Vuno Inc
Glance View

Market Cap
341.7B KRW
Industry
Health Care

VUNO Inc. engages in the development of healthcare algorithms and software solutions. The company is headquartered in Seoul, Seoul. The company went IPO on 2021-02-26. In addition, the Company sells an embolic material product, Nexpear. The firm sells its products in domestic and overseas markets such as Japan, Europe, and the United States.

Intrinsic Value
26 882.59 KRW
Undervaluation 8%
Intrinsic Value
Price
V

See Also

What is Vuno Inc's Total Liabilities?
Total Liabilities
16.7B KRW

Based on the financial report for Dec 31, 2023, Vuno Inc's Total Liabilities amounts to 16.7B KRW.

What is Vuno Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
62%

Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Vuno Inc have been 8% over the past three years , 62% over the past five years .

Back to Top